REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study

Inclusion Criteria:

• Participant has a confirmed asthma diagnosis and has been prescribed NUCALA by theirphysician for the treatment of asthma, as per local label. NUCALA can be initiatedup to 7 days prior to study enrollment.

• No NUCALA use in the 6 months prior to enrollment.

• Participants with greater than or equal to (≥)60 percentage (%) predicted forcedexpiratory volume in 1 second (FEV1) and less than or equal to (≤)4 exacerbationsper year, as confirmed by the physician.

• Other local prescription criteria of NUCALA not described above at NUCALA initiation (e.g., local reimbursement criteria).

• Written informed consent

Exclusion Criteria:

• Investigator concerns about participant's willingness to adhere to biologictreatment for any reason (e.g., cost, behavior, difficulty with access tohealthcare)

• Participants currently on maintenance OCS or intramuscular corticosteroids.

• Participants using omalizumab, reslizumab, dupilumab, tezepelumab, or benralizumabwithin the 6 months prior to enrollment

• Participants participating in an interventional study with a treatment intervention